Explore the words cloud of the DiAMS project. It provides you a very rough idea of what is the project "DiAMS" about.
The following table provides information about the project.
ADVANCED MICROFLUIDICS SA
|Coordinator Country||Switzerland [CH]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-06-01 to 2019-11-30|
Take a look of project's partnership.
|1||ADVANCED MICROFLUIDICS SA||CH (ECUBLENS VD)||coordinator||50˙000.00|
Diabetes is the second more frequent disease in the world with around 422 M cases and about 12% of global health expenditure. Many patients, mostly with type I diabetes, depend on insulin delivery to have a high-quality life and need comfortable, wearable, easy to use and cheap medical devices. In Europe, about 60 M people have diabetes and more than 71 M are estimated by 2040. Around 6 M Europeans have type I diabetes from which about 140.000 are children (the highest world prevalence), making it an European health prority.AMF develops, manufactures and sells microfluidics components for high performance applications. We aim to offering a new solution for insulin treatment for diabetes patients and we have developed a microfluidic technology to serve as a basis for our semi-disposable insulin patch-pump. The use of our intelligent, compact and cost-effective DiAMS will disrupt the field of insulin delivery and make it a safer, more reliable and more mobile for care in hospitals and at home solution. Our system is practically invisible, composed of a patch pump, a continuos glucose monitoring (CGM) and a management interface through a LiNK component that can be controlled through the smartphone. The business opportunities are tremendous because today only Insulet Corporation and Roche offer a product on the patch-pump market, which despite its moderate success have opened the door and let us strongly compete in it thanks to our partially disposable concept and the use if orefilled insulin cartridges. Our technology has many potential applications in drug delivery in the future. DiAMS takes into account the European challenges by making the insulin treatment easier, cheaper, more accurate and more comfortable to patients. In phase 1 we plan to build a detailed feasibility study and business plan to establish the needs for DiAMS commercialization. We estimate a €3.5M funding for phase 2 and potential profits of €59 M after 5 years.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DIAMS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "DIAMS" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
IOT and cloud computing for online medical analysis service platformRead More
ADVANCED TREATMENT OF CONTAMINATED SOILRead More